References
1. The website of the Federal State Statistics Service (Rosstat) “Natural movement of the population in the context of the constituent entities of the Russian Federation”, sections “Infant mortality by the constituent entities of the Russian Federation for January-December 2019”; “Information on mortality of children under 1 year of age due to causes of death in the Russian Federation for January-December 2019”. URL: https://gks.ru/free_doc/2019/demo/edn12-19.htm (in Russian)
2. Site of the Federal State Statistics Service (Rosstat) “Natural movement of the population in the context of the constituent entities of the Russian Federation”, sections: “Infant mortality in the constituent entities of the Russian Federation in January-December 2018”; “Information on mortality of children under 1 year of age due to causes of death in the Russian Federation in January-December 2018”. Moscow: FGBU «TsNIIOIZ» Minzdrava Rossiyskoy Federatsii, 2019: 169 p. (in Russian) URL: https://gks.ru/free_doc/2018/demo/edn12-18.htm (in Russian)
3. The main indicators of the health of mothers and children, the activities of the child welfare and obstetric services in the Russian Federation. Moscow: FSBI «TsNIIOIZ» of the Ministry of Health of the Russian Federation, 2019.169 p. (in Russian)
4. Degtyarev D.N., Zaplatnikov A.L. Intrauterine infections. Cytomegalovirus infection. In: Neonatology: a national guide. Short edition / ed. N.N. Volodin. Moscow: GEOTAR-Media, 2013: 725-31. (in Russian)
5. Neonatology: in 2 volumes / ed. T.L. Gomella, M.D. Cunningham, F.G. Eyal; transl. from English. ed. D.N. Degtyarev. Moscow: BINOM. Laboratoriya znaniy, 2015: 708 p. (in Russian)
6. Rawlinson W.D., Boppana S.B., Fowler K.B., et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet. 2017; 17 (6): e177-88 [Electronic resource]. URL: http://dx.doi.org/10.1016/S1473-3099(17)30143-3.
7. Mussi-Pinhata M.M., Yamamoto A.Y. Natural history of congenital cytomegalovirus infection in highly seropositive populations. J Infect Dis. 2020; 221: 15-22.
8. Leruez-Ville M., Foulon I., Pass R., Ville Y. Cytomegalovirus infection during pregnancy: state of the science. Am J Obstet Gynecol. 2020; 9378 (20): 30198-8.
9. Halwachs-Baumann G., Genser B. Die konnatalezytomegalievirusin-fetion. Wien, 2003: 133 p.
10. Полин Р.А., Спитцер А.Р. Секреты неонаталогии и перинатологии. Пер. с англ. под общ. ред. Н.Н. Володина. Moscow: BINOM, 2013: 624 p. (in Russian)
11. Zaplatnikov A.L., Shakhgildyan V.I., Podzolkova N.M. et al. Is it possible to prevent the consequences of congenital cytomegalovirus infection? (the opinion of the obstetrician-gynecologist, neonatologist and infectiolo-gist) // RMJ. Medical Review. 2018. № 10. P. 45-50. (in Russian)
12. Cytomegalovirus infection in children with autism spectrum disorder: systematic review and meta-analysis. J Autism Dev Disord. 2018; 48 (5): 1483-91.
13. Korndewal M.J., Oudesluys-Murphy A.M., Kroes A.C.M., Vos-sen A.C.T.M., de Melker H.E. Congenital cytomegalovirus infection: child development, quality of life and impact on daily life. Pediatr Infect Dis J. 2017; 36 (12): 1141-7.
14. de Vries J.J.C., van Zwet E.W., Dekker F.W., Kroes A.C.M., Ver-kerk P.H., Vossen A.C.T.M. The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: a population-based prediction model. Rev Med Virol. 2013; 23 (4): 241-9.
15. Wang C., Zhang X., Bialek S., Cannon M.J. Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clin Infect Dis. 2011; 52 (2): e11-3.
16. Leruez-Ville M., Magny J.-F., Couderc S., Pichon C., Parodi M., Bus-sieres L., et al. Risk factors for congenital cytomegalovirus infection following primary and nonprimary maternal infection: a prospective neonatal screening study using polymerase chain reaction in saliva. Clin Infect Dis. 2017; 65 (3): 398-404.
17. Lang T.A., Sesik M. How to describe statistics in medicine. Annotated guide for authors, editors and reviewers / transl. from English, edit. by V.P. Leonov. Moscow: Prakticheskaya meditsina, 2011: 480 p. (in Russian)
18. Kenneson A., Cannon M.J. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007; 17 (4): 253-76.
19. Dollard S.C., Grosse S.D., Ross D.S. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007; 17 (5): 355-63.
20. Townsend C.L., Forsgren M., Ahlfors K., Ivarsson S.-A., Tookey P.A., Peckham C.S. Long-term outcomes of congenital cytomegalovirus infection in Sweden and the United Kingdom. Clin Infect Dis. 2013; 56 (9): 1232-9.
21. CDC. Sexually transmitted diseases treatment guidelines 2002. Morb Mortal Wkly Rep. 2002; 51: 1-80.
22. Letter of the Ministry of Health of the Russian Federation of 13.02.2020, No. 15-4 / 368-07 On clinical guidelines «Normal pregnancy» (ID288, developer of ROAG, approved in 2019)). (in Russian)
23. Kagan K.O., Enders M., Schampera M.S., et al. Prevention of maternal-fetal transmission of cytomegalovirus after primary maternal infection in the first trimester by biweekly hyperimmunoglobulin administration. Ultrasound Obstet Gynecol. 2019; 53 (3): 383-9.
24. Yinon Y., Farine D., Yudin M.H. Screening, diagnosis, and management of cytomegalovirus infection in pregnancy. Obstet Gynecol Surv. 2010; 65: 736-43.
25. Forsgren M. Prevention of congenital and perinatal infections. Euro Surveill. 2009; 14: 2-4.
26. Rahav G. Congenital cytomegalovirus infection - a question of screening. Isr Med Assoc J. 2007; 9: 392-4.
27. Doutre S. Reducing congenital cytomegalovirus infection through policy and legislation in the United States. Microbiol Aust. 2015; 36 (4): 162-4.
28. Shakhgildyan V.I. Diagnosis and treatment of cytomegalovirus infection in pregnant women and newborns Neonatologiya: novosti, mneniya, obuchenie [Neonatology: News, Opinions, Training]. 2017; 3: 70-82. (in Russian)
29. Cahill A.G., Odibo A.O., Stamilio D.M., Macones G.A. Screening and treating for primary cytomegalovirus infection in pregnancy: where do we stand. A decision-analytic and economic analysis. Am J Obstet Gynecol. 2009; 201 (5): 466.e1-7.
30. URL: https://gateway.euro.who.int/en/indicators/hfa_603-7120-births-with-downs-syndrome-per-100-000-live-births/ (date of access July 2, 2020)
31. Kuznetsova V.V., Shahgildyan V.I., Karazhas N.V., Baranova E.B., Serebrovskaya L.V., Shipulina O.Yu., et al. Diagnosis of cytomegalovirus infection in HIV-infected pregnant women and determination of risk factors for antenatal and perinatal infection of fetus with cytomegalovirus. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2005; (2): 24-9. (in Russian)
32. Leung J., Cannon M.J., Grosse S.D., Bialek S.R. Laboratory testing and diagnostic coding for cytomegalovirus among privately insured infants in the United States: a retrospective study using administrative claims data. BMC Pediatr. 2013; 13: 90.
33. Walker S.P., Palma-Dias R., Wood E.M., Shekleton P., Giles M.L. Cytomegalovirus in pregnancy: to screen or not to screen. BMC Pregnancy Childb. 2013; 13: 96.
34. Leyder M. Primary maternal cytomegalovirus infections: accuracy of fetal ultrasound for predicting sequelae in offspring. Am J Obstet Gynecol. 2016; 215 (5): 638.e1-8.
35. Revello M.G., Furione M., Rognoni V., et al. Cytomegalovirus DNAemia in pregnant women. J Clin Virol. 2014; 61: 590-2.
36. Mace M., Sissoeff L., Rudent A., Grangeot-Keros L. A serological testing algorithm for the diagnosis of primary CMV infection in pregnant women. Prenat Diagn. 2004; 24 (11): 861-3.
37. Prince H.E., Lape-Nixon M. Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing primary CMV infection during pregnancy. Clin Vaccine Immunol. 2014; 21 (10): 1377-84.
38. Shahgildyan V.I. Cytomegalovirus infection. In: Lectures on Infectious Diseases: in 2 volumes, 4th ed. / edited by N.D. Yushchuk, Yu.Ya. Vengerov. Moscow: GEOTAR-Media, 2016; (2): 592 p. (in Russian)
39. Enders G., Daiminger A., Bader U., Exler S., Enders M. Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol. 2011; 52 (3): 244-6.
40. Rahav G., Gabbay R., Ornoy A., Shechtman S., Arnon J., Diav-Citrin O. Primary versus nonprimary cytomegalovirus infection during pregnancy, Israel. Emerg Infect Dis. 2007; 13 (11): 1791-3.
41. Mussi-Pinhata M.M., Yamamoto A.Y., Aragon D.C., Duarte G., Fowler
K.B., Boppana S., et al. Seroconversion for cytomegalovirus infection during pregnancy and fetal infection in a highly seropositive population: the BraCHS Study. J Infect Dis. 2018; 218 (8): 1200-4.
42. Shakhgildyan V.I., Yadrikhinskaya M.S., Orlovsky A.A., Shipulina O.Yu., Domonova E.A., Tishkevich O.A. et al. Concentration of CMV DNA in biological materials is the key to diagnosis of cytomegalovirus pneumonia in patients with HIV infection. Zhurnal infektologii [Journal of Infectology]. 2019; 11 (3 suppl 1): 109-17. (in Russian)
43. Stagno S., Ireland K.R. Congenital cytomegalovirus infection. In: S.L. Sacks, S.E. Straus, R.J. Whitley, P.D. Griffiths (eds). Clinical Management of Herpes Viruses. IOS Press, 1995: 329-40.
44. Shahar-Nissan K., Pardo J., Peled O., Krame I., Bilavsky E., Wiz-nitzee A., et al. Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy. In: ID Week. Washington, 2019.
45. Leruez-Ville M., et al. In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study. Am J Obstet Gynecol., 2016; 215 (4): 462.e1-10.
46. Jacquemard F., Yamamoto M., Costa J.-M., Romand S., Jaqz-Aigrain E., Dejean A., et al. Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection. BJOG. 2007; 114 (9): 1113-21.
47. Kimberlin D.W., et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015; 372 (10): 933-43.
48. Seidel V., Feiterna-Sperling C., Siedentopf J.-P., Hofmann J., Hen-rich W., Buhrer C., Weizsacker K. Intrauterine therapy of cytomegalovirus infection with valganciclovir: review of the literature. Med Microbiol Immunol. 2017; 206 (5): 347-54.
49. ShakhgiLdyan V.I., GaLina M.V., Shamshurina M.K., SiLts V.V. The first case of use of vaLgancycLovir use for the treatment of cytomegaLovirus infection in a HIV-infected pregnant woman. EpidemioLogiya i Infekt-sionnye BoLezni [EpidemioLogy and Infectious Diseases]. 2008; (3): 60-5. (in Russian)
50. Petrova G.V., Shakhgildyan V.I., Chistozvonova E.A., Pugacheva T.A., et al. Experience of using the antiviral therapy of generalized congenital cytomegalovirus infection. Detskie infektsii [Children Infections]. 2016; 15 (2): 61-8. (in Russian)
51. NeoCytotect. Instructions for the use of a medicinal product for medical use [Electronic resource]. URL: https://www.rlsnet.ru/tn_index_id_35536.htm (date of access July 2, 2020) (in Russian)
52. Nigro G., Adler S.P., La Torre R., Best A.M. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med. 2005; 353: 1350-62.
53. Visentin S., Manara R., Milanese L., Da Roit A. Early primary cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age. Clin Infect Dis. 2012; 55 (4): 497-503.
54. Revello M.G. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med. 2014; 370 (14): 1316-26.
55. Hughes B.L. A randomized trial to prevent congenital CMV. In: ID Week Washington, 2019.
56. Hamprecht K., Kagan K.-O., Goelz R. Hyperimmune globulin to prevent congenital CMV infection. N Engl J Med. 2014; 370 (26): 2543.
57. Nigro G., Capretti I., Manganello A.M., Best A.M., Adler S.P. Primary maternal cytomegalovirus infections during pregnancy: association of CMV hyperimmune globulin with gestational age at birth and birth weight. J Ma-tern Fetal Neonatal Med. 2015; 28: 1-4.
58. Hamprecht K., Kagan K.O., Goelz R. Hyperimmune globulin to prevent congenital CMV infection. N Engl J Med. 2014; 370: 2543.
59. Coll O., Benoist G., Ville Y., et al. Guidelines on CMV congenital infection (recommendations and guidelines for perinatal practice). J Perinat Med. 2009; 37: 433-45.
60. Yamamoto A.Y., Mussi-Pinhata M.M., Boppana S.B., Novak Z., Wagatsuma V.M., Oliveira P. de F., et al. Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. Am J Obstet Gynecol. 2010; 202 (3): 297.e1-8.
61. Reitter A., Buxmann H., Haberl A., Schlosser R., Kreibich M., Berger A. Incidence of CMV Co-infection in HIV-positive women and their neonates in a tertiary referral centre: a cohort study. Med Microbiol Immunol. 2016; 205 (1): 63-71.
62. Degtyareva A.V., Zubkov V.V., Nepsha O.S. et al. Experience in the use of ganciclovir in the treatment of generalized forms of congenital cytomegalovirus infection. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2012; (5): 103-8. (in Russian)
63. Valganciclovir Effective in Infants With Cytomegalovirus. In: ID Week. 2013. Abstract LB-1. Present October 5, 2013. URL: www.antibi-otic.ru/index.php-article=2367
64. Kimberlin D.W., Jester P.M., Sanchez P.J., et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015; 372 (10): 933-43.